Related Experiment Video

Updated: Mar 24, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Ixabepilone for the treatment of endometrial cancer

Claudia Marchetti1, Ilaria Piacenti1, Ludovica Imperiale1

  • 1a Department of Gynecological and Obstetrical Sciences and Urological Sciences , 'Sapienza' University of Rome , Rome , Italy.

Expert Opinion on Investigational Drugs
|March 8, 2016
PubMed
Abstract

Insights

Ixabepilone, a microtubule-stabilizing agent, shows limited efficacy in improving outcomes for advanced or recurrent endometrial cancer (EC). Further research is needed to define its therapeutic role in this challenging gynecological malignancy.

Area of Science:

  • Gynecological Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • Endometrial cancer (EC) is the most common gynecological cancer with a poor prognosis in advanced stages.
  • Current treatment strategies require enhancement for advanced, recurrent, or metastatic EC.
  • Ixabepilone, a novel microtubule-stabilizing agent, has shown efficacy in metastatic breast cancer.

Purpose of the Study:

  • To evaluate the clinical efficacy of ixabepilone in patients with advanced, recurrent, or metastatic endometrial cancer.
  • To determine if ixabepilone improves clinical outcomes in endometrial cancer treatment.

Main Methods:

  • Systematic review of preclinical and clinical studies on ixabepilone in endometrial cancer.
  • Literature search of PubMed, clinicaltrials.gov, and major international congress abstracts.
  • Analysis of phase I and II studies and peer-reviewed articles.

Main Results:

  • Ixabepilone demonstrated limited efficacy in improving clinical outcomes for advanced or recurrent endometrial cancer.
  • The therapeutic role of ixabepilone in endometrial cancer remains uncertain based on current data.

Conclusions:

  • Advanced or recurrent endometrial cancer presents a significant clinical challenge.
  • Ixabepilone's efficacy in endometrial cancer is limited, and its future role is ill-defined.
  • Clinicians should be aware of ixabepilone's profile when managing gynecological tumors.
Keywords:
Endometrial cancerchemotherapyepothilonesixabepilonemetastaticnew agentsrecurrent disease

More Related Videos

Endoscopy Guided Photoablation of Endometrial Cysts using a 980 nm Laser with a Contact Fiber in Mares07:07

Endoscopy Guided Photoablation of Endometrial Cysts using a 980 nm Laser with a Contact Fiber in Mares

Published on: July 16, 2020

5.2K
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
937
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
855
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
786
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K